Presentation on theme: "French National Institute of Health and"— Presentation transcript:
1 French National Institute of Health and InsermFrench National Institute of Health andMedical ResearchCreated in 1964 from the National Institute of Hygiene and Hospital ResearchWorking through theMinistries for Research and Health
2 (62% of total budget dedicated to salaries) Inserm : key figures335 Inserm laboratories19 research centers41 Clinical Investigation Centers (CIC)Budget 2006 : 700 M€Total staff:(2 500 physicians) of which5 100 Inserm employees(62% of total budget dedicated to salaries)An active patent portfolio of 572 families374 French and foreign firms are partners of Inserm56 start-up companies based on Inserm technology
3 What is Inserm ?The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public HealthAll fields of research are covered in these domains80% of the 354 research units are located in University hospitalsResearch units with 8 years mandate with mid-term (4 year) evaluation. Stringent evaluationInvestigator- driven projects - AVENIR programmeClose collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.
10 Evolution of the clinical medicine field (publications 1995 – 2005)
11 Science (IF=30,927) and Nature (IF=29,273) Que les articles, ni lettres ni revuesNew England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)Science (IF=30,927) and Nature (IF=29,273)
15 Science (IF=30,927) and Nature (IF=29,273) Que les articles, ni lettres ni revuesNew England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)Science (IF=30,927) and Nature (IF=29,273)
16 OrganizationBottom-up initiatives: selection based on quality and innovationNetworks focused on major public health issues
17 Cardiovascular Bone and Joint Diseases 2.2% Diabetes 2.6% Hepatitis 3.1%Geneticdiseases10.5%16.8%CancerCardiovascular9.1%17.1%Immunologyof which 9.3%for neurologicdisorders20.6%NeurosciencesInfectious diseasesand microbiology(without Aids and Hepatitis)8.3%Public health7.5%Handicap5.1%Nutrition4.8%AIDS3.7%Research laboratories being often involved in more that one domain, the overall distribution is over 100 %
18 « Interdisciplinarity » Inter-research agencies programmes :- CNRS : SPI, STIC, chemistry, etc..- INRIADedicated research units in specific infrastructures:ex: CNG, NanotechnologyDedicated research Programmes :- Nanotechnology- « Systems biology »Training
19 Inserm : creation of research centers Objectives and main characteristics:Critical mass (100 to 300 staffs),Mutualisation and IntegrationInternational visibility, AttractivenessAssessment criteria:Scientific excellenceQuality of the management :Governing structure, mutualised administration & managementTechnology transfert and research outcomesSharing of technical facitiliesCoordination of scientific events and programmesImplementation of research training programmesInternational scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)
21 19 Research Centers in 2007 1- Paris 6, Pluri-thematic Some exemples:1- Paris 6, Pluri-thematic2- Paris 6, Neurophysiology4- Paris 5, Pluri-thematic5- Créteil, Pluri-thematic6- Lilles, Pluri-thematic7- Dijon, Cancer/Nutrition8- Bordeaux, Neurophysiology9- Grenoble, Neurophysiology10- Grenoble, Cancer11- Toulouse, Pluri-thematic
24 Research infrastructures National Genomic Research Consortium: CNRGNational Sequencing CenterNational Genotyping CenterRegional Genopoles Core FacilitiesBiosafety-level 4 laboratoryLocal and regional technological plateformsClinical Research Infrastructures
25 Regional clustersCanceropoles, other thematic poles (Neuropole, …)Competitivity clusters (Industry)Regional poles for research in Neurosciences, etc.
27 10 National & 23 Regional infrastructures National infrastructures :Regional infrastructures :Animal experimentsFunctional investigationsTranscriptomicsProteomicsIn vivo imagingStructural biologyCellular imagingSequencingElectron microscopyLilleRouenCaenParisNancyStrasbourgRennesOrléansDijonNantesLyonBordeauxGrenobleClermont-FerrandPoitiersNiceToulouseMarseilleMontpellier1Rousset2310 National&23 Regionalinfrastructures
28 Main Inserm’s priorities « Researchers » : Careers, Training & MobilityTo focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approachTo establish Inserm in a European and International contextTo develop public/private partnerships
29 Career, Training and Mobility Researchers :Career, Training and Mobility
30 NEW CAREER TRACKS General principles To strengthen the status of young scientists; to recognize, evaluate and promote scientific qualities: high level fixed term contracts and the program AVENIRTo offer tenure positions to researchers: mid and long-term research plansTo increase research career development and mobility and foster partnerships:INTERFACE RESEARCH GRANTS
31 Le recrutement chercheur Contrats jeunes chercheurs « Juniors »:5 ans (évaluation intermédiaire à 3 ans)30%: AvenirSuivi: mission chercheursChargés et Directeurs de rechercheContrats post-doctorants 12 mois (24 mois ?)(Postes verts)
32 Post-doctoral career track Inserm-NIH (appel d’offres permanent) Candidats proposés par l’Inserm après leur thèse:3 ans de post-doctorat dans l’un des instituts desNIH « intra-muros ».Suivi personalisé (mission chercheurs), évaluationde la qualité du stage post-doctoralContrat Junior (5ans, avec évaluation à 3 ans)Contrat temporaire universitaire ou HURecrutement: EPST, Université etc ..
33 (Labos internationaux) Contrats d’interface pour chercheurs et ingénieurs de rechercheHôpitalCHU, CLCC383Industrie6Université60CRDRIRInternationaux(Labos internationaux)2Agences SanitairesN: 5Inserm (ISFIC)Chercheurs: 50Ingénieurs: 37
34 Contrats d’Interface Médecins hospitaliers et HU et Enseignants-chercheurs HOPITALINSERM88 PH, MCU-PH,PU-PHUNIVERSITEINSERM11 enseignants-chercheurs
35 Career tracks in Inserm Junior, temporary (5years with 3year intermediateevaluation), high level contractsAvenir programEuropean programs: EURYI, ERCPermanent positions for senior scientists
36 AVENIR ProgrammeEligibility: Young scientists with permanent or temporary position, cliniciansAim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualitiesEach successful candidate is allocated:A yearly budget of 60 K eurosMinimum lab space of 50 m2Personnel: 1 post-graduate collaborator and 1 graduate studentEach successful young scientist receives a salary for 5 years
37 Tenure career track: General principles Academic freedom Design tenure career tracks with reasonable security:Academic freedomReinforce interface with partners: intersectoral mobility:Hospitals: clinical research, health policy issuesHealth agenciesUniversities: teaching, making scientific informationavailable to the society- Industry: technological transfer and valorisationEuropean mobility ?
38 Interface contracts : General principles Based on :a permanent position + temporary, 3-5 year contractsTo reinforce interactions with partners and mobilityHospitals: clinical research, medical issuesHealth agencies: health policy issuesUniversities: teaching, making scientific information available to the societyIndustry: technological transfer and valorisationEuropean partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)
39 Tenure position + 3-5 year contracts: " 2/3 – 1/3 " New Career TrackTenure position year contracts: " 2/3 – 1/3 "UniversitiesIndustryUniversity hospitalsCancer centersCRDRInsermDGS / Health agenciesInternational (Hospitals, universities)
40 David SASSOON Born on May 25, 1959 Presently : Professor of Molecular Biology, Mount Sinai Medical School , New York, USAJoint Inserm/AFM/Paris VI operationResearch theme: muscle developmentDR1 permanent position + interphase contract (AP-HP)Inserm UnitChair of excellence 2004 (MR), AvenirLaboratory space: 750 m2: Pitié-Salpêtrière hospitalAccompagnying measures:- IR Paris VI- Temporary contractsAssistance with school, housing…
41 Thomas BAUMERT, M.D. Born on May Presently: Assistant professor, Dept of Medicine University of Freiburg, GermanyInserm/ULP/HUS Strasbourg joint operationResearch theme: HCVLaboratory: Virology laboratory in StrasbourgDR2 permanent position + Interphase contract HUSInserm unit, Avenir: in progressTemporary contractsAssistance with school, housing…PU-PH
42 Matthew ALBERT, M.D. PhD Born on December 9, 1970 Was: Clinical Scholar, Rockfeller University and Resident Clinical Pathology The New York Hospital New York, USAInserm/Pasteur Institute/Necker Hospital joint operationResearch theme: Dendritic cell biology/HCV/CancerLocation: Pasteur Institute ParisSince June 2003 : Inserm DR2 permanent position + Interphase contract AP-HP + Team Leader Pasteur InstituteInserm Avenir Unit and Pasteur Institute UnitTemporary contracts (junior scientists, MDs)Assistance with housing
43 (62% of total budget dedicated to salaries) Inserm : key figures325 Inserm laboratories19 research centers41 Clinical Investigation Centers (CIC)Budget 2006 : 700 M€Total staff:(2 500 physicians) of which5 700 Inserm employees(62% of total budget dedicated to salaries)An active patent portfolio of 572 families374 French and foreign firms are partners of Inserm56 start-up companies based on Inserm technology
44 Interface Contract grants for MDs Reinforce research activities of clinicians and university research assistants and professors3-5 year contracts for clinicians : assistant professors andprofessors, university employeesGrant paid by Inserm to hospitals and universities to be used for :- clinical and teaching activities: temporary positions- financing research activities
45 The School of InsermA 3 year Educational programme which leads to a Master and MD-PhD trackFirst year of Inserm School - Second year of Medical School :Special School Intensive Training Session in FebruaryJune: Competitive ExamSecond year of Inserm School - Third year of Medical School6 month full time Research Clerkship in an Inserm Research LaboratoryThird year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree
46 and Translational research strategy Clinical researchand Translational research strategy
47 A continuum from Basic to Clinical Research: Translational researchTo develop dedicated performing Research InfrastructuresTo sponsor clinical studies and innovative therapeutic clinical trialsTo ensure appropriate training of Physicians to Research skills and vice-versaTo integrate these actions in a European context:ECRIN, Biological resource centers: Roadmap ESFRIInnovative medecine platform
48 Clinical trials Inserm Inserm Inserm Proof of concept Basic Phases I-IIaBiotherapyBasicResearchPreclinical studies :Proof of conceptPhasesIIb-IIIPhase IVCohorts[CRC]
49 The new “challenges” of clinical research in Europe To support development of new therapeutic molecules :Innovative BASIC research approachesInnovative CLINICAL research: therapeutic and physio-pathological studiesin between : dedicated research infrastructuresTo support Innovation and Biotechnology sector developmentTo satisfy end-users (patients) requirements
50 Inserm, as a major actor of the Clinical Research in France and in Europe To set-up an efficient Translational research towards the benefits of patientsTo develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI)To sponsor clinical studies and innovative therapeutic clinical trialsTo ensure appropriate training of Physicians to Research skills and vice-versa : School of InsermTo built a continuum from Basic research to Clinical Research
51 Clinical research infrastructures 200620012002200320042005Clinical research centers4217212831Tissues Banks471630Cohorts118131135142147Registries3529Networks229
52 Infrastructures de recherche clinique Et en santé des populations 2006< 2000200020012002200320042005CICCIC-ECCIC Biothérapie2371141101721+24Collections biologiques47-1630Cohortes14799117131135142Registres293135Réseaux2692235
53 Les CICCIC « généralistes »CIC-EC: épidémiologie et gestion des essais cliniquesCIC-Biothérapie2007: CIC-»innovations technologiques »
54 CIC et Unités InsermPromotions Inserm: 20% demandées par les CICEtudes et essais cliniques réalisées dans les CIC:environ 20-30% viennent des unités
55 Budget de base + projets Comment renforcer les collaborations?Postes d’accueilpour internesContrats chercheursJuniors 5 ansServices de soinset de biologieCHUContrats d’interfaceCICEquipes de rechercheTranslationnelleBudget de base + projetsUnités de rechercheInserm
56 CIC, CIC-BT and CIC-EC (2006) BichatHenri Mondor(94 Créteil)Pitié-SalpêtrièreNecker Enfants MaladesRobert DebréSaint-LouisSaint-AntoineHEGPLes15-20CochinIGR (Villejuif)LilleRennesNantesToursNancyStrasbourgLyonMontpellierMarseilleBordeauxToulouseGrenobleRouenSaint-EtienneDijonBrestClermont-FerrandBesançonCIC (23)CIC-EC (7)CIC-BT (11)Saint-PierreIle de la Réunion
57 Key Figures of the Clinical Research 797 on-going Clinical trialsmonocentricsFrench multicentricsEuropean and international multicentricsAbout patients expected to be included and currently involved120 beds devoted to clinical trialsA staff of professionals101 physicians, pharmacists,27 biostatisticians, psychologists, researchers69 nurses51 Clinical research technicians, administrative
58 Thematic networks of CIC Cardiovascular : 14 CIC Coordinator : F. Zannad, CIC de Nancy Metabolic diseases and diabetes : 9 CIC Coordinator : P. Petit, CIC de Montpellier Gastro-Enterology-Hepatology : 9 CIC Coordinator : C. Libersa, CIC de Lille Thrombosis : 3 CIC Coordinator : H. Decousu, CIC de St Etienne Cancer Coordinator : F. Calvo, CIC de St Louis (AO-HP) Neurosciences : 13 CIC Coordinator : Ph. Damier, CIC de Nantes Paediatric : 8 CIC Coordinator : E. Jacqz-Aigrain, CIC Robert Debré de Paris
59 National networks of Clinical Research Centres Clinical Trial Units Pan-European network of Clinical research infrastructures: the ECRIN network of INSERMECRIN : European Clinical Research Infrastructures NetworkNational networks of Clinical Research Centres Clinical Trial UnitsSwedenSweCRINECRIN should be considered as a tool that will allow:- to access research facilities certified as compliant with the GMP/GLP standards in Europe- to access expertise in the preparation and conduct of trans-national clinical trials- to access scientific and ethic evaluationsQuébecFRSQ-GEREQDenmarkDCRINGermanyKKSOthernetworksEFGCPFranceCIC & UECSpainSCReNItalyCIRM & IRFMN
60 ECRIN : a Platform of Integrated services to multinational studies Integrated services (one-stop shop) to multinational studies:1 - interaction with ethics commitees2 - interaction with competent authorities, regulatory affairs3 - drug dispensing4 - adverse event reporting5 - data management6 - study monitoring7 - management of biological samples
61 Biological Resources Centres a networking action at both National and European Levels
62 LilleCaenRennesNantesToursNancyStrasbourgLyonMontpellierMarseille3219DijonGrenobleToulouseAmiensAngersBrestReims36IDFBRCs in France National policy of the Ministry for Research and the National Research Agency to support the development of BRCs
63 Biological Resources Centres Key components to:Industry : external sourcing: innovative targets, hits and leads, biomarkers, clinical studies…Academic : valorisation, technology tranfer and dissemination of knowledge.
64 Biological Resources Centres "Service providers and repositories of the living cells, genomes of organisms, and information relating to heredity and the functions of biological systems" (O.E.C.D. definition).Infrastructures that qualify biological samples (DNA, RNA, proteins…), provide samples for national projects and keep samples for the future (inheritage).
65 European Biological Resources network (EBRC) The necessity of a European network :To co-ordinate European scientific programs and policies : 7th PCRDTo develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials.Valorisation of knowledgeAttractiveness of public research and development of innovative SMEs.
66 The European BRCs brings together: Service and work facilities made up of collections that satisfy the EU research objectivesConservation sites made up of patrimonial reference collections : national collections, cryobanks, rare tissue or tumour collections…Ongoing European initiatives :Contact at Inserm :
67 From Cohorts to Biomarkers Cohorts : key issues for InsermAccess to "thematic" cohorts of patients (cancer, mental diseases, etc.)Access to cohorts of healthy volunteers for prospective studies, genetic studies, etc.The Challenges of BiomarkersClinic : prediction, diagnostic and prognosisBio-pharmaceutical industry : Valorisation of Research in partnership with industry.
68 Platforms for GMP production State of the art :Platforms for production of therapeutic vectors : Nantes (Atlantic biothérapies), Généthon, etc.Platforms for production of bio-medicines : LFB, Genopole Ile-de-France, Vivalis, Lipidomix, etc.Platforms for production of therapeutic virus : HeidelbergPerspectives : availability of GMP productsPartnership with Inserm-TransfertCosts sharingEuropean dimension : ESFRI / IMI
69 IMI : Innovative Medicines for Europe European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.Inserm is the French representative in the Member states contact Group of IMI
70 OrganizationBottom-up initiatives: selection based on quality and innovationNetworks focused on major public health issues
71 National Research Programs To bring together all parties interested in a given research area:Research institutesUniversitiesHospitalsSanitary AgenciesCharities and FoundationsMedical SocietiesSocial protection agenciesPatient AssociationsIndustryTo launch calls for proposals open to the scientific community regardless of institutional affiliationTo support young investigators, scientists and clinicians
72 National Research Programmes Main missions of the Inserm National Research Programmes :To support new/young research teamsTo support organisation of seminars and workshops : prospective studies and follow-up of actionsTo identify projects that could be submitted to FP7 or some other international programmes (NIH, etcCollaborations with the NIH: seminars and grantsTo reinforce partnerships withPatients associationsMedical specialised scientific societiesIndustry
73 National Research Programmes National Research Program on Cardiovacular Diseases PNRCNational Research Program on Diabetes PNRDin collaboration with CNRSNational Research Program on Human Nutrition PRNHin collaboration with INRANational Research Program on Bone and Joint Diseases PRO-AVirtual Institute for Public Health Research IVRSPNational Research Program on sense organs PNRV
74 ANR,INCA ANRS….. National Research Programs Networks ProjectsANR,INCAANRS…..National ResearchProgramsNetworksPNRDPNRCPRNHATC BIOTHERAPYATC DRUGSSYSTEMS BIOLOGYATC ALCOHOLPRO-AIVRSPPNR-DermatoPNR-O. SensPNR-Hépato-GEPNR-Endo-ReproEUROPENIHMissions:Recruitments:Avenir etc.Research structures:centresProjects: cohorts etc..
75 National Research Agency (ANR) Created in February 2005 with a total yearly budget: around 800 M€ (approx. 25 % dedicated to Biomedical sciences)Main objectives :support to basic research projectssupport to translational research (partnerships)Launched calls for thematic and "free" programmes :Cardiovascular diseases, Obesity, DiabetesNeurosciences, psychiatryMicrobiology- ImmunologyRare diseasesProjects of scientific excellence : 370 k€ for a 3-year duration and involving 3 to 4 partners (in average)
76 National Research Agency (ANR) Main figures in 2005:35 calls for proposals published5652 proposals submittedSuccess rate : 25,7% => 1454 projects / 4500 research teamsBreakdown of budget available / scientific domains :30% Non-thematic25% Matter and Information19% Biology and Health18% Sustainable energy and environment8,8% Ecosystems and sustainable developmentSpecific actions and support to Partnership & Competitiveness, Young researchers (including chairs of excellence)
77 Inserm - ANR Programme Management Launch of the Thematic programme "Biology and Health"In Cardiovascular, Obesity, DiabetesNeurosciences, neurology and psychiatryMicrobiology - ImmunologyRare diseasesHealth and environmentHealth technologiesEmerging and maturation of biotechnology projectsIn Physio-pathology of human diseasesMicrobiology- Immunology- Emerging diseasesResearch and Innvovation in Biotechnology Emerging and maturation of biotechnology projectsBiological Resources sampling in Health
81 The main axes EU Prospectives (ESF, EUROHORCS, etc.) Participation in European programmes : RTD FP & Public Health FPInfrastructures - ESFRI (ECRIN, …)Researchers’ mobility within EU programmes andBilateral actions: Common Research projects - Associated laboratories - Joint-units abroad
82 Multilateral cooperation actions Participation to the European Research and Public health programmesInserm andThe 6th Framework Programme of the EUInserm andThe 7th Framework Programme of the EU( )
84 Inserm-Transfert SAPrivate subsidiary of the French National Institute for Health and Medical Research (Inserm)Created by Inserm in 2001, funded up to 4,5 M€ by Inserm and comprising actually 50 peopleIncrease researchers’ awareness of technology transfer and company creationIdentification and promotion of innovative projects emerging from Inserm’s laboratoriesLaunch of a new seed fund called “Inserm-Transfert Initiative” with three major investors in the biotech field (Sofinnova, Ventech, CDC Entreprise) - Capital amount = 4.2 M€
85 International project management 21 projects under management (6 Network of Excellence, 3 Integrated Projects, 12 STREP) and 8 projects under negociationTotal budget for all projects under management over 200 million €Creation of value by up-coming licensing and SME’s participationBiotech start-up creation and PatentingInserm-Transfert has invested 800 kEuros in 11 new biotech companies that have raised 85 million euros600 patents' family - 60 to 90 New demands/year licensing agreements
86 Bilateral cooperations’ actions Researchers' mobility (short-medium term, Interface Contract grants)Research networks ( EU programmes , NIH, Bill Gates etc..)Associated laboratoriesJoint Research unit abroad
87 Bilateral cooperations’ actions Researchers' mobility (short-medium term, Interface Contract grants)European research networks at the bilateral level and within the EU programmesEuropean Associated laboratoriesJoint Research unit abroad
88 Cooperations between Inserm and German Partners (1) One formal agreement with DFG : short-term exchange of researchers based on 2 years projects538 cooperation undertaken since 1985Main city: Berlin, Bonn, Munich, Freiburg, HeidelbergMain thematic areas : Cellular Biology,Neurosciences, Immunology, Cancer, Genomics, Cardiovascular diseases,…51 German Post-doc, Researchers and Fellows in the Inserm's research units in 2005Cooperation with Freiburg:35 projects, mainly in dermatology, neurosciences, virology, toxicology, etc
89 Cooperations between Inserm and German Partners (2) Associated laboratories under preparation (HEGP/La Charité - Freiburg/Strasbourg)A Joint Unit Abroad - U701 Inserm / DKFZ (J. Rommelaere - Heidelberg) - Cancer and VirotherapyIn the frame of the 6th EU Framework programme :59 European research projects mainly in the LSH priority : 16 NoE - 27 IP - 14 STREPs - 2 CA (84 Inserm's teams - 83 German teamsFuture collaborations within the FP7 :Health priority, IMI, Infrastructures (ECRIN, BRCs)
90 Cooperations between Inserm and Hungarian Partners (1) 40 cooperation projects undertaken since => more than 61 common publicationsMain cities: Budapest, Szeged, DebrecenMain Partner Institutions : Hungarian Academy of Sciences, Semmelweis University, University of Debrecen etc.Main thematic areas : Neurosciences, Cellular Biology, Molecular Biology, Cardiovascular Physiopathology, Biochemistry…10 Hungarian Post-docs, Researchers and Fellows within Inserm's research units in 200590
91 Cooperations between Inserm and Hungarian Partners (2) In the frame of the 6th EU Framework programme :13 European research projects mainly in the LSH priority : 5 NoEs - 7 IPs - 1 STREP (17 Inserm's teams Hungarian teams)Future collaborations within the FP7 :Health priority, IMI, Infrastructures (ECRIN, BRCs)91
92 Bilateral cooperations’ tools Associated LaboratoryInserm Unit AbroadScientific driven2x4 years mandateSynergies: competencies and facility accessCo-funding by Inserm and Associated partnersTemporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)Networks, EU research projects
93 Bilateral cooperations’ tools European Associated LaboratoryInserm Unit AbroadScientific driven2x4 years mandateSynergies: competencies and facility accessCo-funding by Inserm and Associated partnersTemporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)EU research projects - Networks
94 European Associated laboratory (LEA) Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)Lille : M. Capron U547 / Bruxelles : M. Goldman (IMI)Joint Research Unit in Europe:Université de Glasgow / C. Doerig U609DKFZ / J. Rommelaere U701Associated laboratories(under preparation)Milan / BordeauxRome / VillejuifRome / NiceFerrara / ParisDundee / ToulouseFreiburg / StrasbourgBerlin / ParisBarcelona / ParisPorto / ToulouseDundeeGlasgowBruxellesBerlinFreiburgHeidelbergPragueMilanBarcelonaFerraraPortoRome
95 European Associated Laboratories (LEA) Toulouse Prague:D. Langin (Inserm U586) - V. Stich (Univ. Charles)Lille Brussels:M. Capron (Inserm U547) - M. Goldman (Univ. Libre de Bruxelles)Toulouse Dundee:AC Prats (Inserm U589) - JC Bourdon (Univ. Dundee)Bordeaux Milan:A. Bikfalvi (Inserm E 113) - L. Bello (Univ. Degli Studi)Nice Rome:G. Meneguzzi (Inserm U 634) - G. Zambruno (IDI-IRCCS)Villejuif Paris Sud Rome:D. Samuel (Inserm U 785) - M. Levrero (Univ. La Sapienza)Montpellier London:K. Ritchie (Inserm U 888) - G. Thornicroft (King’s College of London)Strasbourg Freiburg:T. Baumert (Inserm U 748) - H. Blum (Univ. of Freiburg)Villejuif Paris Sud Barcelona:T. Moreau (Inserm U780) - J. Antό (PRBB, IMIM-CREAL)Bordeaux Porto:L. Bordenave (Inserm U 577) - M. Barbosa (IBMC, INEB)DundeeGlasgowLondonBrusselsHeidelbergPragueFreiburgMilanPortoBarcelonaRomeJoint Research Unit in Europe:Glasgow University / C. Doerig (Inserm U609)DKFZ / J. Rommelaere (Inserm U701)
96 MontrealLavalMontréalLos AngelesSeoulBeijingNew YorkHaïfaTokyoRabatWuhanIrvinePittsburghKyotoNanjingDallasShanghaiDohaGuangzhouSingapourRio de JaneiroINSERM UnitAssociated LaboratoryIn preparationBuenos Aires
97 “2/3 base salary + 1/3 supplementation” « European and International Interface Contract » grants ?Pilot action under preparationPermanent position by Inserm + temporary contract:“2/3 base salary + 1/3 supplementation”
98 Japan is the first partner of Inserm in Asia (ca Japan is the first partner of Inserm in Asia (ca. 180 collaborative projects).An increase between 2000 and 2006 (+40%).About 20 Japanese scientists within Inserm units each year.2% of Inserm publications are with Japan.Long term relationship Inserm-JSPS : 80 projects funded since 1994Inserm-Japan
99 Inserm-Japan : New Avenues of Collaborations International Associated laboratory with the RIKEN DRI on lipidomics study of membrane microdomains.Inserm Unit in Kyoto University Graduate School of Medicine on trans-ethnic comparative human genomicsA clinical research partnership between Inserm and its partners and the Translational Research Center of Kyoto University.A collaborative agreement with the Riken so as to foster our partnership in :Stem cell biology (Riken CDB)Immunology (Riken RCAI)Neurosciences (Riken BSI)
100 Inserm International Laboratories and Inserm Unit in Japan TokyoTokyoKyotoINSERM UnitAssociated LaboratoryIn preparation
101 Evaluation of participation of Inserm to the 6th FP as in March 2006 Inserm is involved in 99 projects (including coordination of 24 projects)
102 Accompanying measures of Inserm Project preparation mainly within the FP6 programme : partnership with Inserm Transfert SAThe « Europe Task Force » actions:Information and promotionPre-evaluation of potentiaI EU projectsCoordination / partnership of InsermS&T, administrative, legal and financial follow-upFollow-up of the next FP7 (Thematic priorities, JTI, …)
103 Missions of the European Affairs division of the DPRE InformationEuropean project preparation and follow-up, in close collaboration with Inserm-Transfert (the private subsidiary of Inserm)To represent Inserm at Brussels and near other European institutionsTo follow European policies development and to evaluate opportunitiesTo set-up and coordinate bilateral cooperations
104 The European Affairs division A dedicated TeamContact person in each connected/involved Inserm’ departments: The EUROPE Task ForceA permanent staff in Brussels (CLORA)A contact in LondonA competence centre in Project management within Inserm-TransfertA specific budget
105 The « Europe Task Force » of Inserm DRIDRCT- Lobbying - Information- Marie-Curie programme- Training sessions and information targeted to:Administrative staffsProjects' coordinatorsConsortium agreementsPreparation & managementof EU projectsCosts models- Budgets - Contractual issuesInfrastructuresERA-NETs - EthicsCLORADG RESEARCH ECInserm'sLaboratoriesInserm TransfertADRsDFLDRHEuropeInnovativeStart-upDAPSDPRERegional & NationalPartnershipsEuropeanClinical researchJTI/IMIEND- Bilateral cooperation - LEA/Unit abroad
106 Inserm-Transfert as the vector of Inserm‘s Technology Transfer UniversitiesInserm-TransfertInternationalinstitutionsPharmaceuticalcompaniesBiotech companiesInvestors/ VCsInserm
107 Inserm-Transfert activities: forwarding science into business Technology Transfer& LicensingInternationalProjects ManagementIndustrial ProjectsManagementProof-of-ConceptvalidationBiotech CompaniescreationSourcing &IP Management
108 Career, Training and Mobility Researchers :Career, Training and Mobility
109 “2/3 base salary + 1/3 supplementation” « European Interface Contract » grants ?Pilot action under preparation with European institutions (Italy, Portugal, UK, Spain, Germany,..)Permanent position by Inserm + temporary contract:“2/3 base salary + 1/3 supplementation” Co-funding strategy : one of the European Marie Curie schemes ?
110 Extension of such programs to European mobility - Marie Curie Fellowship scheme ? Heterogeneity of scientists career tracks: tenure positions provided by universities vs. research agencies etc…However: the senior positions offered by each country may be viewed as a “core” status which salary can be maintained by the institution for scientists who wish to work in other countries.As an incentive to mobility, the host institutions might add temporary grants (Interface grants) obtained by the scientist who moves to another country, provided by: hospitals, universities, industry, others…Basis of the program: reciprocity, attractivity …Future prospective :a more "homogenized" tenure position career track: (salary, social security benefits and taxes, EU-wide health card etc.)- Implication of European Marie Curie programs ?
111 Inserm’s web site : www.inserm.fr Contacts :Inserm’s web site :Department of French Regional and European Strategic PoliciesAnne Bisagni, Director :Philippe Arhets, Deputy Director :Cécile Bergouignan, Bilateral cooperation :Human Resources : Researchers task forceAnne-Marie Laffaye, School of Inserm, Avenir :Richard Salives, Marie Curie Programme :
Your consent to our cookies if you continue to use this website.